Document:

ex10-1.htm

Exhibit 10.1

AMENDMENT AGREEMENT NO. 3

This AMENDMENT AGREEMENT NO. 3 (this “Agreement”) effective as of ____, 2015 (the “Effective Time”), between MabVax Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), and the investor signatory hereto (the “Purchaser”), hereby consents to certain waivers and modifications to the Registration Rights Agreement, as amended by the Amendment Agreement dated as of June 9, 2015 (the “Original Amendment Agreement”) and the Amendment Agreement dated August 4, 2015 (“Second Amendment Agreement” and such Registration Rights Agreement as amended by the Original Amendment Agreement and the Second Amendment Agreement, the “Registration Rights Agreement”) executed in connection with the purchase by the Purchaser of Units (as defined below) of the Company’s securities  pursuant to that certain Subscription Agreement governing the sale of the Units described below (the “Subscription Agreement”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Registration Rights Agreement or the Subscription Agreement.  Except as specifically agreed to, waived or consented to herein, the terms of the Transaction Documents shall remain in full force and effect.

RECITALS

WHEREAS, the Company and certain investors (including the Purchaser) (the “Buyers”) entered into the Subscription Agreements between March 31, 2015 and April 10, 2015, pursuant to which the Company sold and the Buyers signatory thereto purchased units of the Company’s securities (the “Units”) with each Unit consisting of one share of the Company’s common stock, par value $0.01 per share (the “Common Stock”) (or, at the election of any Buyer who, as a result of receiving Common Stock would hold in excess of 4.99% of the Company’s issued and outstanding Common Stock, shares of the Company’s newly designated  0% Series E Convertible Preferred Stock (the “Preferred Shares”)) and a thirty month warrant (the “Warrants”) to purchase one half of one share of Common Stock at an initial exercise price of $1.50 per share, upon the terms and subject to the conditions set forth in the Subscription Agreement;

WHEREAS, in connection with the Purchaser’s purchase of the Units, the Company and the Purchaser entered into the Registration Rights Agreement whereby the Company agreed to register for resale, 25% of (i) the shares of Common Stock issued as part of the Units and (ii) issuable upon conversion of the Preferred Shares, in accordance with the terms of the Registration Rights Agreement;

WHEREAS, on June 9, 2015, the Company entered into Original Amendment Agreements with Buyers representing, in total, an aggregate of at least 60% of the Registrable Securities, including the Lead Investor (as such terms are defined in the Transaction Documents) in order to amend the original definition of “Filing Date” in the Registration Rights Agreement to August 5, 2015;

WHEREAS,  on August 4, 2015, the Company entered into Second Amendment Agreements with Buyers representing, in total, an aggregate of at least 60% of the Registrable Securities, including the Lead Investor in order to further amend the original definition of “Filing Date” in the Registration Rights Agreement to October 9, 2015;

WHEREAS, the Company has requested that the Purchaser agree to further amend the Registration Rights Agreement and the Subscription Agreement to suspend the Company’s registration obligations under the Registration Rights Agreement during any time in which the “Standstill” provision set forth in Section 5(u) of the Subscription Agreement is in effect; and

WHEREAS, concurrently herewith, Buyers (other than the Purchaser) (the “Other Buyers”), are executing amendments identical to this Agreement (the “Other Agreements” and, together with this Agreement, the “Agreements”).

  

-1-

  

 

NOW THEREFORE, in consideration of the respective covenants and promises contained herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows, intending to be legally bound hereby:

1.           Registration Rights.  The Purchaser hereby agrees that Section (a) of Article 1.2 of the Registration Rights Agreement shall be amended and restated as follows:

“(a) On or prior to the Filing Date, the Company shall prepare and file with the Commission a registration statement covering the Registrable Securities for an offering to be made on a continuous basis pursuant to Rule 415. The registration statement shall be on Form S-1 or, if the Company is so eligible, on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-1 or Form S-3, as the case may be, in which case such registration shall be on another appropriate form in accordance herewith) and shall contain (unless otherwise directed by Investors holding an aggregate of at least 60% of the Registrable Securities on an “as converted” and “as exercised” basis including the approval of the Lead Investor) substantially the “Plan of Distribution” attached hereto as Annex A. The Company shall cause the registration statement to become effective and remain effective as provided herein. The Company shall use its reasonable best efforts to cause the registration statement to be declared effective under the Securities Act as soon as possible and, in any event, by the Effectiveness Date. The Company shall use its reasonable best efforts to keep the registration statement continuously effective under the Securities Act until all Registrable Securities covered by such registration statement have been sold, or may be sold without the requirement to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, as determined by the counsel to the Company (the “Effectiveness Period”). Notwithstanding the foregoing provisions, the Company’s registration obligations set forth in this Section 1.2(a) and in this Agreement generally (including any requirements to file, amend or cause or maintain the effectiveness of such registration statement and the incurrence of any liquidated damages in connection therewith) shall be suspended during any period when the “Standstill” provision set forth in Section 5(u) of the Subscription Agreements is in effect.”

2.           Subscription Agreement.  The Purchaser hereby agrees that Section 5(u) of the Subscription Agreement shall be amended to add the following provisions at the end of such section:

“Additionally, and notwithstanding anything to the contrary herein, the Company’s registration obligations set forth in Section 7 herein and in the Registration Rights Agreement (including any requirements to file, amend or cause or maintain the effectiveness of such registration statement and the incurrence of any liquidated damages in connection therewith) shall be suspended during any period when the restrictions set forth in this Section 5(u) are in effect.

3.           Liquidated Damages.  The Purchaser hereby waives any and all damages, penalties and defaults  related to the Company’s not filing the registration statement by the Filing Date or any damages, penalties and defaults should the Registration Statement not be declared effective by the Commission by the Effectiveness Date (as such terms are originally defined in the Registration Rights Agreement).

 

4.           Effectiveness.  This Agreement and the amendments contemplated herein shall be effective upon the Company obtaining this Agreement executed by the Purchaser along with executed Other Agreements from Other Buyers, representing, in total, an aggregate of at least 60% of the Registrable Securities, including the consent of the Lead Investor (as such terms are defined in the Transaction Documents).

  

-2-

  

 

5.           Independent Nature of Purchaser's Obligations and Rights.  The obligations of the Purchaser under this Agreement or any other Transaction Document are several and not joint with the obligations of any Other Buyer, and the Purchaser shall not be responsible in any way for the performance of the obligations of any Other Buyer under any Transaction Document or Other Agreement.  Nothing contained herein or in any Other Agreement or any other Transaction Document, and no action taken by the Purchaser pursuant hereto, shall be deemed to constitute the Purchaser and Other Buyers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchaser and Other Buyers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this Agreement, any Other Agreement or any other Transaction Document, and the Company acknowledges that the Purchaser and the Other Buyers are not acting in concert or as a group with respect to such obligations or the transactions contemplated by this Agreement, any Other Agreement and any other Transaction Document.  The Company and the Purchaser confirm that the Purchaser has independently participated in the negotiation of the transactions contemplated hereby with the advice of its own counsel and advisors.  The Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement, any Other Agreement or out of any other Transaction Documents, and it shall not be necessary for any Other Buyer to be joined as an additional party in any proceeding for such purpose.

 

6.           No Third Party Beneficiaries.  This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

7.           Non-Public Information.  The Company acknowledges and agrees that the amendments, waivers and consents contemplated hereby do not constitute material modifications to the Transaction Documents and consequently, as of the Effective Time, the Company shall have disclosed all material, non-public information (if any) provided to the Purchaser by the Company or any of its Subsidiaries or any of their respective officers, directors, employees or agents in connection with the transactions contemplated hereby and by the Transaction Documents.

 

8.           Counterparts.  This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which taken together shall constitute but one and the same instrument.  In the event that any signature is delivered by facsimile transmission or by an e-mail which contains a portable document format (.pdf) file of an executed signature page, such signature page shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

 

9.           No Strict Construction.  The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

 

10.           Headings.  The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.

 

11.           Severability.  If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties.  The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

  

-3-

  

 

12.           Scope.  Except as explicitly set forth herein, the Transaction Documents remain unmodified and in full force and effect.

 

13.           Further Assurances.  Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

14.           Successors and Assigns.  This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns in accordance with the terms of the Subscription Agreement.

 

15.           Governing Law; Jurisdiction; Jury Trial.  All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.  Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.  Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.  EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS CONSENT OR ANY TRANSACTION CONTEMPLATED HEREBY

 

16.           Most Favored Nation.  The Company hereby represents and warrants as of the date hereof and covenants and agrees from and after the date hereof that none of the terms offered to any person with respect to the amendments, waivers and consents contemplated hereby, is or will be more favorable to such person than those of the Purchaser under this Agreement.  The provisions of this Section 16 shall apply similarly and equally to each Other Agreement.

 

[Signatures appear on following page.]    

  

-4-

  

 

IN WITNESS WHEREOF, the Purchaser and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written above.

	  	
COMPANY:

MABVAX THERAPEUTICS HOLDINGS, INC.

 

	  	
By:

Name:

Title:

 

IN WITNESS WHEREOF, the Purchaser and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written above.

 

	  	
PURCHASER:

	  
	  	  	  	  
	  	
By:

	
                                                                

	  

 

-5-Exhibit 10.1

 

SETTLEMENT AND LICENSE AGREEMENT

 

This SETTLEMENT AND LICENSE AGREEMENT (this
“Agreement”) is made and entered into as of the date of the last signature required by this Agreement (the “Effective
Date”) by and between Plaintiff Enzo Life Sciences, Inc., a corporation organized and existing under the laws
of the State of New York, having offices at 10 Executive Boulevard, Farmingdale, NY 11735 (“Enzo”) and Defendant
Affymetrix, Inc., a corporation organized and existing under the laws of the State of Delaware, having offices at 3420 Central
Expressway, Santa Clara, CA 95051 (“Affymetrix”). Enzo and Affymetrix are individually referred to herein as
a “Party,” and collectively as the “Parties.”

 

WITNESSETH

 

WHEREAS, Enzo has alleged that Affymetrix infringes U.S. Patent
No. 7,064,197 (“the ‘197 patent”) in an action styled Enzo Life Sciences, Inc. v. Affymetrix, Inc., No.
1:12-cv-433-LPS, pending in the United States District Court for the District of Delaware (the “Litigation”); and

 

WHEREAS, Affymetrix denies all liability in the Litigation;
and

 

WHEREAS, Affymetrix has alleged that it does not infringe the
‘197 patent, and further, that the ‘197 patent is invalid and unenforceable; and

 

WHEREAS, Enzo disputes Affymetrix’s allegations of invalidity,
unenforceability, and non-infringement; and

 

WHEREAS, the Parties now desire to settle the Litigation and
to provide and receive certain releases, licenses and covenants not to sue, all on the terms and conditions set forth herein; and

 

WHEREAS, this Agreement reflects a settlement and compromise
between the parties under Federal Rule of Evidence 408 with respect to Enzo’s claims and Affymetrix’s defenses in the
Litigation, including without limitation on the disputed issues of patent validity, enforceability, and infringement;

 

NOW, THEREFORE,
in consideration of the above recitals and the mutual covenants hereinafter contained, the Parties agree as follows:

 

SECTION 1: DEFINITIONS

 

As used in this Agreement, the following terms shall have the
following meanings:

 

“Affiliate” means, with respect to a Party,
all future wholly-owned subsidiaries of such Party that are created by the Party in the ordinary course of business or as a result
of an internal reorganization of the Party (e.g., not an acquisition of, acquisition by, or merger with another Person) and only
for so long as that entity is a wholly-owned subsidiary of such Party and any Person that, as of the Effective Date, is directly
or indirectly controlling, controlled by, or under common control with, such Party. For purposes of this Agreement, “control”
means the ability to control the direction of the management and operations of the subject Person, whether through

    	 

    	

    

ownership, contract or otherwise. Control will be presumed where
a Party has ownership of 50% or more of the outstanding voting shares of the Person. Notwithstanding anything to the contrary herein,
the following Persons are not, and cannot be considered, Affiliates of Affymetrix for the purposes of this Agreement so long as
any patent infringement litigation or royalty obligation concerning the Licensed Enzo Patent remains pending between Enzo and that
Person (or any Affiliate of that Person): Abbott Laboratories; Abbott Molecular, Inc.; Agilent Technologies, Inc.; Becton, Dickinson
and Company; Becton, Dickinson Diagnostics, Inc.; Geneohm Sciences, Inc. (now part of Becton Dickinson); Gen-Probe, Inc. (now part
of Hologic, Inc.); Hologic, Inc.; Illumina, Inc.; Life Technologies Corporation (now part of Thermo Fisher Scientific, Inc.); Roche
Molecular Systems, Inc. (part of Hoffmann-La Roche AG); Roche Diagnostics Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics
Operations Inc. (part of Hoffmann-La Roche AG); and Roche Nimblegen, Inc. (part of Hoffmann-La Roche AG); or their respective Affiliates.

 

“Licensed Affymetrix Products” means any
past, current and future products and services, product lines, devices, systems, assays, components, kits, hardware, software,
or any combination of the foregoing which are made, used, sold, offered for sale, or imported by Affymetrix or its Affiliates that,
but for the license granted in this Agreement, would infringe a Valid Claim of the Licensed Enzo Patent.

 

“Licensed Enzo Patent” means (i) U.S. Patent
No. 7,064,197; (ii) any patents and patent applications claiming priority to or through, or sharing a common priority claim with,
any of the foregoing; and (iii) any foreign counterparts, re-issues, re-examinations, renewals, substitutes, claim amendments made
in post-grant proceedings including IPR and PGR proceedings, extensions, continuations, continuations-in-part, continuing prosecution
applications, divisionals, and national phase filings of any patents and patent applications covered in subparts (i) and (ii).

 

“Person” means an individual, trust, corporation,
partnership, joint venture, limited liability company, association, unincorporated organization, or other legal entity.

 

“Third Party” means any Person or entity
other than the Parties to this Agreement and their Affiliates.

 

“Covered Third Party Accused Products” means
Third Party products and services that include as an element thereof any Licensed Affymetrix Products.

 

“Valid Claim” means a claim of an issued
patent that has not expired or been finally held invalid or unenforceable by a court or administrative body of competent jurisdiction
from which no appeal can be or is taken.

 

SECTION 2: LICENSE, RELEASES, AND COVENANTS

 

2.1 License. Subject to the terms and conditions hereof,
including Affymetrix’s timely payment of the Payment under Section 3.1, Enzo hereby grants to Affymetrix and its Affiliates
a fully paid-up non-exclusive, non-transferable (except as set forth in Section 5), worldwide license under the Licensed Enzo Patent
to make, have made, use, import, export, distribute, sell, offer for

    	 

    	

    

sale, and practice all processes and methods in connection with,
the Licensed Affymetrix Products.

 

Affymetrix shall not have the right to sublicense or otherwise
grant, in whole or in part, licenses under the Licensed Enzo Patent. The license granted herein shall not extend to cover any products
of a Third Party that acquires or is acquired by Affymetrix or its Affiliates (whether by merger, consolidation, share acquisition,
or acquisition of all or substantially all assets or otherwise), including without limitation for products made, used, imported,
exported, distributed, sold, offered for sale, developed, advertised, and practiced by such Third Party before the date of such
acquisition. The license granted herein shall not include any rights to the Licensed Enzo Patent other than those expressly provided
by this section. No license or immunity is granted under this Agreement by Enzo, either directly or by implication, estoppel, or
otherwise, to any Person acquiring Licensed Affymetrix Products for the modification or combination by such Person of Licensed
Affymetrix Products with other items other than in the ordinary manner in the ordinary course of use of Licensed Affymetrix Products,
or as specified in Sections 2.2 and 2.3, or as otherwise permitted by the law of patent exhaustion.

 

2.2 Enzo Release of Affymetrix. Subject to the terms
and conditions hereof, including Affymetrix’s timely payment of the Payment under Section 3.1, Enzo, on behalf of itself
and its Affiliates, releases, acquits and absolutely and forever discharges Affymetrix and its Affiliates, and each of their officers,
directors, managers, employees, agents, and attorneys (“Affymetrix Released Persons”) from any claim, counterclaim,
demand, allegation, damage, loss, debt, liability, account, reckoning, indemnity, obligation, cost, expense, lien, attorneys’
fee, any other action or cause of action of any kind or nature, whether now known or unknown, suspected or unsuspected, matured
or unmatured, asserted or unasserted, in law or equity, for (i) infringement of the Licensed Enzo Patent to the extent related
to the business of Affymetrix and occurring before the Effective Date; (ii) the claims, defenses, and counterclaims asserted in,
and the conduct of, the Litigation; and (iii) the conduct of settlement negotiations (except for representations or obligations
expressly included in this Agreement). Enzo also provides a limited release to customers, distributors, or users of any Licensed
Affymetrix Products for any claim, based on conduct occurring before the Effective Date, of infringement of the Enzo Licensed Patent
by Licensed Affymetrix Products and Covered Third Party Accused Products but only to the extent that Affymetrix’s own conduct
with respect to such customer, distributor, or user infringement would give rise to a colorable claim against Affymetrix for direct
or indirect infringement under 35 U.S.C. §§ 271(a), (b), (c), and/or (f) (and/or a claim based on the same types of indirect
infringement theories asserted against Affymetrix in the Litigation) but for the licenses, releases, and covenants granted to Affymetrix
herein. For the avoidance of doubt, to the extent any customers, distributors, or users of any Licensed Affymetrix Product infringe
the Enzo Licensed Patent for any reason that would not also give rise to a colorable claim against Affymetrix for direct or indirect
infringement under 35 U.S.C. §§ 271(a), (b), (c), and/or (f) (and/or a claim based on the same types of indirect infringement
theories asserted against Affymetrix in the Litigation) but for the licenses, releases, and covenants granted to Affymetrix herein,
such infringement is not released hereunder.

 

The scope of this release is fixed as of the Effective Date.
Except as expressly set forth herein, this release shall not apply to any Person, including without limitation any Third Party,
or any

    	 

    	

    

business, assets, or products thereof, acquired by Affymetrix
or its Affiliates (whether by merger, consolidation, share acquisition, or acquisition of all or substantially all assets or otherwise)
after the Effective Date.

 

2.3 Limited Enzo Covenant Not To Sue On Covered Third Party
Accused Products. Subject to the terms and conditions hereof, including Affymetrix’s timely payment of the Payment under
Section 3.1, Enzo, on behalf of itself and its Affiliates, covenants during the term of this Agreement not to sue Affymetrix’s
distributors, customers, and users for (i) infringement of the Licensed Enzo Patent by a Licensed Affymetrix Product, or (ii) infringement
of the Licensed Enzo Patent by a Covered Third Party Accused Product using or containing a Licensed Affymetrix Product, but only
to the extent that Affymetrix’s own conduct with respect to such customer, distributor, or user infringement would give rise
to a colorable claim against Affymetrix for direct or indirect infringement under 35 U.S.C. §§ 271(a), (b), (c), and/or
(f) (and/or a claim based on the same types of indirect infringement theories asserted against Affymetrix in the Litigation) but
for the licenses, releases, and covenants granted to Affymetrix herein. For the avoidance of doubt, to the extent any customers,
distributors, or users of any Licensed Affymetrix Product infringe the Enzo Licensed Patent for any reason that would not also
give rise to a colorable claim against Affymetrix for direct or indirect infringement under 35 U.S.C. §§ 271(a), (b),
(c), and/or (f) (and/or a claim based on the same types of indirect infringement theories asserted against Affymetrix in the Litigation)
but for the licenses, releases, and covenants granted to Affymetrix herein, this covenant does not apply. This covenant not to
sue is non-assignable by Affymetrix or by any of Affymetrix’s distributors, customers, and users who benefit from this covenant
not to sue.

 

2.4 Affymetrix Release of Enzo. Affymetrix, on behalf
of itself and its Affiliates, releases, acquits and absolutely and forever discharges Enzo and its Affiliates, and each of their
officers, directors, shareholders, managers, employees, agents, and attorneys from any claim, counterclaim, demand, allegation,
damage, loss, debt, liability, account, reckoning, indemnity, obligation, cost, expense, lien, attorneys’ fee, any other
action or cause of action of any kind or nature, whether now known or unknown, suspected or unsuspected, matured or unmatured,
asserted or unasserted, in law or equity, arising out of or related to: (i) infringement of the Licensed Enzo Patent to the extent
occurring before the Effective Date; (ii) the claims and defenses asserted in, and the conduct of, the Litigation; and (iii) the
conduct of settlement negotiations (except for representations or obligations expressly included in this Agreement).

 

2.5 Covenant Not to Challenge. After the Effective Date
and for so long as Affymetrix’s license is in force, Affymetrix further covenants that, except as (1) required by law or
(2) in defense of an action for infringing the Licensed Enzo Patent brought against it or its Affiliates, or against its or their
agents, representatives, suppliers, vendors, contractors, manufacturers, distributors, licensees, resellers, licensees, users,
and customers (direct or indirect) involving any Licensed Affymetrix Products, it shall not knowingly and voluntarily contest (or
assist in the contest) in any forum, including Federal Courts, whether under 28 U.S.C. §§ 2201-2202 or not, the United
States Patent and Trademark Office, and/or the International Trade Commission, that the Licensed Enzo Patent is valid and enforceable;
provided, however, nothing in this Agreement shall prevent Affymetrix or its Affiliates from complying with or responding to any
court or governmental order or subpoena relating to the Licensed Enzo Patent. Notwithstanding the

    	 

    	

    

foregoing, nothing in this Agreement will preclude Affymetrix
and its Affiliates from making any disclosure, providing information or producing documents as required by law, court order or
legal process (including, without limitation, litigation related to discovery and/or subpoena), even if made in connection with
a proceeding challenging the validity or enforceability of one or more of the Licensed Enzo Patent, and any such disclosure will
not be considered a breach of this Agreement. It is understood that Affymetrix’s and its Affiliates’ providing factual
statements regarding Licensed Affymetrix Products or any Third Party products containing them in response to a validly propounded
subpoena will not be considered as assisting in the contest as used above. Affymetrix reserves the right to raise any and all defenses
and counterclaims, including, but not limited to, invalidity and unenforceability of the Licensed Enzo Patent, and to otherwise
contest the validity and enforceability of the Licensed Enzo Patent in any forum, that it could have raised in the Litigation,
if the Licensed Enzo Patent is asserted based on Licensed Affymetrix Products or Third Party products containing them against Affymetrix,
its Affiliates, customers, licensees, partners or users after the Effective Date; and Enzo reserves the right to raise any and
all claims and defenses in opposition.

 

2.6 Limited Standstill. Each Party agrees that it shall
not, and that it shall cause each of its Affiliates or representatives not to, file or otherwise bring any action or lawsuit alleging
patent infringement against the other Party for a period of three (3) years after the Effective Date of this Agreement or until
the termination of this Agreement, whichever is earlier (“Standstill Period”). Nothing in this Section 2.6 shall enlarge
or otherwise modify the licenses, releases, or covenants set out in this Agreement. The foregoing provision is personal to the
Parties, is non-assignable (except as set forth in Section 5.2), and does not apply to any other Person. Further, it shall not
prevent either Party from engaging in discussions with the other Party or any other Person regarding the licensing of its patents
or from enforcing its patents against any Person other than a Party. During this Standstill Period, any patent infringement claim
that one Party has against the other shall be tolled and any damages will accrue and be recoverable to the full extent permitted
by 35 U.S.C. § 286. For clarity, nothing shall prevent the Parties from seeking damages after the Standstill Period terminates
for patent infringement occurring during the Standstill. If either Party violates this Standstill agreement, the other Party shall
be free to immediately end the Standstill Period. If a complaint for patent infringement is filed after expiration of the Standstill
Period, no Party may rely on the Standstill Period as a basis for any claim, counterclaim, or defense, including without limitation
an assertion of laches. Notwithstanding the foregoing, a Party still may assert any claim, counterclaim, or defense available,
including without limitation an assertion of laches, to the extent it does not specifically rely on the Standstill Period as a
basis. For the avoidance of doubt, nothing in this provision or any other provision of this Agreement shall prevent either Party
from intervening in patent litigation between the other Party and a Third Party based on any indemnity or other contractual obligation
that either Party owes to such Third Party.

 

2.7 Acquisitions. The licenses, releases, and covenants
set forth above shall exclude any products of another Person that is acquired (whether by merger, consolidation, share acquisition,
or acquisition of all or substantially all assets or otherwise) by Affymetrix or its Affiliates on or after the Effective Date.

    	 

    	

    

2.8 Modifications and Combinations In Manner Other Than Ordinary
Course. No license or immunity is granted under this Agreement by Enzo, either directly or by implication, estoppel, or otherwise,
to any Person acquiring Licensed Affymetrix Products for the modification or combination by such Person of Licensed Affymetrix
Products with other items other than in the ordinary and intended manner in the ordinary course of use of Licensed Affymetrix Products,
or as specified by Sections 2.2 and 2.3, or as otherwise permitted by the law of patent exhaustion.

 

2.9 No Extinguishment Of Other Outstanding Royalty Obligations.
For the avoidance of doubt, nothing in this Agreement shall operate to extinguish the obligation of any Person to pay royalties
to Enzo arising from an obligation outside of this Agreement (including via contract, operation of law, judicial ruling, or otherwise).

 

2.10 No Other Rights. No rights
or covenants are granted under any patents except as expressly provided herein, whether by implication, estoppel or otherwise.
No right to grant covenants, rights, sublicenses, or to become a foundry for Third Parties is granted under this Agreement. The
Parties agree that, except as expressly set forth herein, the licenses, releases and covenants set forth in this Agreement (including
Section 2) expressly exclude any methods, systems, products, services and/or components of any Third Party. The Parties further
agree that, except as expressly provided herein, this Agreement does not cut off Enzo’s rights to enjoin, control or extract
royalties with respect to such Third Party’s methods, systems, products, services and/or components.

 

SECTION 3: MONETARY CONSIDERATION

 

3.1 Payment. As partial consideration for this
Agreement and the dismissal by Enzo of the Litigation hereunder, Affymetrix agrees to pay to Enzo a total of ten million U.S.
Dollars ($10,000,000.00) (“Payment”), payable by Affymetrix to Enzo no later than ten (10) business days
following the Effective Date of this Agreement in lawful money of the United States, in immediately available funds, by wire
transfer to the following account: # # #

 

3.2 Taxes / Costs. Each Party acknowledges that this
Agreement may have U.S. federal and state tax (collectively, “Tax”) or other consequences, and that the Party is not
relying on any other Party for advice, representations or communications as to any potential Tax or other consequences. This Agreement
is enforceable regardless of its Tax or other consequences. The Parties agree that they shall bear their own costs and attorneys’
fees relating to or arising from the Litigation and to the documentation and negotiation of this Agreement.

    	 

    	

    

3.3 Dismissal. Within three (3) court days after the
Payment of the consideration to Enzo under this Section 3 has cleared, the Parties shall cause their respective counsel to execute
and file the stipulated motion in the form set forth in Exhibit A dismissing with prejudice all of Enzo’s claims
against Affymetrix in the Litigation. The Parties shall promptly proceed with any and all additional procedures needed to dismiss
the Litigation as set forth above, with each Party to bear its own costs and attorneys’ fees. The Parties also agree to submit
to the court appropriate stipulations and proposed orders for extensions of time for all due dates in the Litigation so that neither
Party is required to incur unnecessary expenses in the Litigation between the Effective Date and the date the Litigation is dismissed.
The Parties acknowledge and agree that this Agreement is enforceable according to its terms with respect to final dismissal with
prejudice of all claims and counterclaims in the Litigation.

 

3.4 No Admission of Liability. This Agreement is the
result of a compromise and will not at any time be considered as an admission of liability or responsibility, or lack thereof,
on the part of Enzo or Affymetrix. By entering into this Agreement, neither Affymetrix nor any of its Affiliates is conceding that
it acted wrongfully in any fashion whatsoever. Except as expressly set forth in Section 3.1, Affymetrix and its Affiliates expressly
deny that they are liable to Enzo in any way.

 

3.5 Full Settlement. The Parties agree that this Agreement
is in full and complete settlement of the rights and obligations of the Parties in connection with the Litigation. This Agreement
may be pleaded as a defense to any action, suit or claim and may be used as a basis for an injunction against any such action,
suit, claim, or other proceeding of any type which may be prosecuted, initiated or attempted in violation of the terms hereof.
A Party is entitled to recover from the other adverse party reasonable attorneys’ fees and other related legal expenses incurred
in defending against any suit, action or claim brought or attempted by the other party in violation of the terms of this Agreement.

 

SECTION 4: TERM AND TERMINATION

 

4.1 Term. The term of this Agreement shall commence upon
the Effective Date and shall continue until the expiration of the enforceability period of the Licensed Enzo Patent, unless earlier
terminated as set forth in Section 4.2 below.

 

4.2 Termination. If Affymetrix fails to make the payment
set forth in Section 3.1 in the time frame required by Section 3.1, then Enzo may terminate this Agreement immediately upon further
written notice to that effect and the license, releases, and covenants granted by Section 2 of this Agreement shall immediately
terminate, be deemed null and void ab initio, and be of no force and effect.

 

SECTION 5: ASSIGNMENT

 

5.1 Assignment. The license and other rights granted
by Enzo in this Agreement are personal to Affymetrix. Except as otherwise permitted in this Section, Affymetrix may not assign,
delegate, or otherwise transfer this Agreement or any license or rights hereunder without the prior written consent of Enzo. The
limitations on assignment set forth in Section 5 do not apply to an internal

    	 

    	

    

reorganization of a Party or its Affiliates (re-incorporation
or the like). Any other purported assignment, delegation, or transfer without the prior written consent of Enzo will be null and
void ab initio and without effect. Nothing herein expressed or implied will give or be construed to give any Person who
is not a Party any legal or equitable rights hereunder.

 

5.2 Permitted Assignment by Affymetrix. Notwithstanding
the provisions of Section 5.1, Affymetrix may assign its rights under this Agreement, in whole or in part, without Enzo’s
prior written or oral consent, to a Person with whom Affymetrix is merged or consolidated, or who acquires all or substantially
all of Affymetrix’s business subject to the Litigation; provided however, that (1) this Agreement shall not be assigned to
multiple Persons; (2) any such assignment of rights will not extend to products or services of such Person that pre-existed the
acquisition (or natural evolutions or extensions thereafter); (3) any such assignment of rights shall not relieve such Person from
any obligations that such Person may have under this Agreement; and (4) Affymetrix obtains from such Person a written agreement
to be bound by the terms and conditions of this Agreement and furnishes the same to Enzo. In the event that Affymetrix does not
continue to exist as a distinct operating entity (such as a wholly-owned subsidiary) after the transaction, the rights of Affymetrix
hereunder so assigned only extend to Licensed Affymetrix Products existing as of the date of the transaction and natural evolutions
of Licensed Affymetrix Products created after the date of the transaction, and will not otherwise extend to any products, services,
or activities of the Person prior to, on or after the date of the transaction. The releases and covenants provided by Affymetrix
and its Affiliates shall run with the rights being assigned or transferred and shall be binding on any permitted successors-in-interest,
transferees, or assigns thereof. For avoidance of doubt, any such assignment of rights will not extend to any Third Party products
or services existing prior to the time of transaction or natural evolutions or extensions thereof. Any purported assignment, delegation,
or transfer under this Section 5.2 that does not comply with the foregoing will be null and void ab initio and without effect.

 

5.3 Further Restriction on Assignment by Affymetrix:
Notwithstanding the provisions of Sections 5.1 and 5.2, in no event may this Agreement, including the license and rights granted
hereunder, be assigned, delegated, or otherwise transferred without Enzo’s prior written consent to any of the following:
Abbott Laboratories; Abbot Molecular, Inc.; Agilent Technologies, Inc.; Becton, Dickinson and Company; Becton, Dickinson Diagnostics,
Inc.; Geneohm Sciences, Inc. (now part of Becton Dickinson); Gen-Probe, Inc. (now part of Hologic, Inc.); Hologic, Inc.; Illumina,
Inc.; Life Technologies Corporation (now part of Thermo Fisher Scientific, Inc.); Roche Molecular Systems, Inc. (part of Hoffmann-La
Roche AG); Roche Diagnostics Corporation (part of Hoffmann-La Roche AG); Roche Diagnostics Operations Inc. (part of Hoffmann-La
Roche AG); and Roche Nimblegen, Inc. (part of Hoffmann-La Roche AG); or any of the respective Affiliates of any of the foregoing
(each a “Restricted Entity”), so long as any patent infringement litigation concerning the Enzo Licensed Patent remains
pending between Enzo and the respective aforementioned Restricted Entities. For the avoidance of doubt, a Restricted Entity’s
acquisition of Affymetrix by stock purchase, reverse triangular merger, or similar transaction does not constitute an assignment
of the Agreement by Affymetrix where Affymetrix (or its successor entity) continues to exist as a distinct operating entity (for
example, as a wholly-owned subsidiary of the Restricted Entity) after the date of the acquisition, provided

    	 

    	

    

that the licenses, covenants, and releases granted herein shall
extend only to Licensed Affymetrix Products existing as of the date of the acquisition and will not otherwise extend to any products,
services, or activities of the acquiring Restricted Entity prior to, on or after the date of the acquisition.

 

5.4 Permitted Assignment by Enzo. All license rights
and covenants contained herein shall run with the Licensed Enzo Patent, as it applies to the license rights and covenants contained
in Sections 2.1 through 2.6, inclusive, and shall be binding on any successors-in-interest or assigns thereof. Any assignment of
the Licensed Enzo Patent to any other Person shall be subject to this Agreement.

 

SECTION 6: MISCELLANEOUS PROVISIONS

 

6.1 Representations:

 

6.1.1 Plaintiff Representations: Enzo
represents and warrants that: (i) as of the Effective Date, Enzo and/or its Affiliates own the Licensed Enzo Patent, and have the
right to grant the license, releases and covenants with respect to the Licensed Enzo Patent set forth herein; (ii) as of the Effective
Date, it has not assigned or otherwise transferred to any other Person any rights to the Licensed Enzo Patent that would prevent
Enzo from conveying the rights set forth herein; and (iii) the person executing this Agreement on behalf of Enzo has the full right
and authority to enter into this Agreement on Enzo’s behalf.

 

6.1.2 Affymetrix Representations: Affymetrix
represents and warrants that: (i) as of the Effective Date, Affymetrix has the right to grant the releases and covenants set forth
herein; and (ii) the person executing this Agreement on behalf of Affymetrix has the full right and authority to enter into this
Agreement on Affymetrix’s behalf.

 

6.1.3 Disclaimer of Representation.
Nothing in this Agreement shall be construed as (i) a representation or warranty by Enzo as to the scope, validity, or enforceability
of any patent; (ii) a representation or warranty that the manufacture, use, or sale of any products will not utilize or infringe
any intellectual property rights; and (iii) any obligation by Enzo to pay annuities or otherwise maintain any patents in force
in any country.

 

6.2 Confidentiality. From and after the Effective Date,
neither Party shall disclose the existence or terms of this Agreement except:

 

6.2.1 with the prior written consent of the other Party;

 

6.2.2 to any governmental body having jurisdiction
and specifically requiring such disclosure;

 

6.2.3 in response to a valid document request
or subpoena or as otherwise may be required by law, legal process or order of a court, provided a protective order is in place
that limits disclosure of such information to outside counsel only and the disclosing Party provides the other Party with written
notice at least ten (10) business days prior to disclosure to permit the

    	 

    	

    

other Party the opportunity to object and/or to seek a court-entered
protective order or comparable court-ordered restriction, and shall reasonably cooperate with the other Party in its efforts to
obtain that protective order and take all other reasonable actions in an effort to minimize the nature and extent of such disclosure
and obtain confidential treatment to the extent available;

 

6.2.4 for the purposes of disclosure in connection
with the Securities and Exchange Act of 1934, as amended, the Securities Act of 1933, as amended, and any other reports filed with
the Securities and Exchange Commission (expressly including, but not limited to, Form 8K disclosures), or any other filings, reports
or disclosures that may be required under applicable laws or regulations;

 

6.2.5 to a Party’s accountants, legal
counsel, tax advisors and other financial and legal advisors and other professional advisors in their capacity of advising the
party in such matters, subject to obligations of confidentiality and/or privilege at least as stringent as those contained herein;

 

6.2.6 with obligations of confidentiality
at least as stringent as those contained herein, to a counterparty in connection with a proposed merger, acquisition, financing
or similar transaction.

 

6.2.7 in connection with tax audits or to
fulfill its corporate financial reporting obligations under GAAP;

 

6.2.8 with obligations of confidentiality
at least as stringent as those contained herein, by any Party and its Affiliates as required to enforce this Agreement or establish
rights hereunder;

 

6.2.9 to officers, key shareholders and/or
employees with a need to know, attorneys, accountants and directors, who are under obligations of confidentiality (which may include
professional responsibility obligations) at least as stringent as those contained herein; and

 

6.2.10 to its Affiliates, who are similarly
bound by this Agreement or under obligations of confidentiality at least as stringent as those contained herein.

 

6.2.11 to Third Parties who make, sell, offer
to sell, export, import, or distribute any Licensed Affymetrix Product or who make, sell, for offer to sell any Covered Third Party
Accused Product, and who have a need to know, under obligations of confidentiality at least as stringent as those contained herein.

 

Notwithstanding anything else in this Agreement to the contrary,
a Party may also disclose to anyone any information that is publicly available, through no breach by any Party of the confidentiality
obligations hereunder.

    	 

    	

    

6.3 Notices. All notices required or permitted to be
given hereunder shall be in writing and shall be delivered by hand, or, if dispatched by prepaid air courier, with package tracing
capabilities or by registered or certified airmail, postage prepaid, addressed as follows:

 

If to Enzo:

 

Dr. Elazar Rabbani

Enzo Life Sciences, Inc.

527 Madison Avenue

New York, NY 10022

 

Copy to (which does not constitute notice):

 

Michael Stadnick

Desmarais LLP

230 Park Avenue

New York, NY
10169

 

If to Affymetrix:

 

Siang Chin

Senior Vice President and General Counsel

Affymetrix, Inc.

3420 Central Expressway

Santa Clara, CA 95051

 

Copy to (which does not constitute notice):

 

Peter Root

Kaye Scholer LLP

Two Palo Alto Square, Suite 400

3000 El Camino Real

Palo Alto,
CA 94306

 

Such notices shall be deemed to have been served when received
by addressee. Either Party may give written notice of a change of address and, after notice of such change has been received, any
notice or request shall thereafter be given to such Party as above provided at such changed address.

 

6.4 Publicity. Neither party will issue a press release
or any other public announcement regarding this Agreement or the settlement of the Litigation unless the other Party provides prior
consent in writing. Notwithstanding the foregoing and Section 6.2 above, upon inquiry either Party may state that Enzo and Affymetrix
have entered into a settlement agreement.

 

6.5 Governing Law / Jurisdiction. This Agreement and
matters connected with the performance thereof shall be construed, interpreted, applied and governed in all respects in accordance
with

    	 

    	

    

the laws of the United States of America and the State of Delaware,
without reference to conflict of laws principles. Enzo and Affymetrix agree (a) that all disputes and litigation regarding this
Agreement, its construction and matters connected with its performance be subject to the exclusive jurisdiction of the state and
federal courts in the District of Delaware (the “Court”), and (b) to submit any disputes, matters of interpretation,
or enforcement actions arising with respect to the subject matter of this Agreement exclusively to the Court. The Parties hereby
waive any challenge to the jurisdiction or venue of the Court over these matters.

 

6.6 Sophisticated Parties Represented by Counsel. The
Parties each warrant and represent that (i) they are sophisticated parties represented at all relevant times during the negotiation
and execution of this Agreement by counsel of their choice, and that they have executed this Agreement with the consent and on
the advice of such independent legal counsel; (ii) they and their counsel have determined through independent investigation and
robust, arm’s-length negotiation that the terms of this Agreement shall exclusively embody and govern the subject matter
of this Agreement, (iii) it investigated the facts pertinent to this Agreement as it deemed necessary, (iv) no other Person or
Party, nor any agent or attorney of a Party, made any promise, representation or warranty whatsoever, express or implied, not contained
in this Agreement concerning the subject matter of this Agreement to induce it to execute this Agreement, (v) it has not executed
this Agreement in reliance on any promise, representation or warranty whatsoever, express or implied, not contained in this Agreement
concerning the subject matter of this Agreement, and (vi) it has not executed this Agreement in reliance on any promise, representation
or warranty not contained herein. The Parties included this paragraph to preclude any claim that any Party was fraudulently induced
to execute this Agreement and to preclude the introduction of parol evidence to vary, interpret, supplement or contradict the terms
of this Agreement.

 

6.7 Bankruptcy. The Parties acknowledge and agree that
all rights and licenses granted by Enzo under or pursuant to this Agreement are, and will otherwise be deemed to be, for purposes
of Section 365(n) of the United States Bankruptcy Code, as amended (the “Bankruptcy Code”), licenses of rights to “intellectual
property” as defined under Section 101 of the Bankruptcy Code. The Parties agree that, notwithstanding anything else in this
Agreement, Affymetrix and its Affiliates, as the licensee of such intellectual property rights under this Agreement, will retain
and may fully exercise all of its rights and elections under the Bankruptcy Code (including, without limitation, a Affymetrix and
its Affiliates’ right to the continued enjoyment of the rights and licenses granted by Enzo under this Agreement). Notwithstanding
the foregoing, this Agreement shall be deemed and treated as an executory contract under Section 365 of the Bankruptcy Code and
is subject to the restrictions on assumption and assignment in section 365(c). Further, this provision shall not alleviate or contravene
the restrictions on assignments and acquisitions set forth in this Agreement.

 

6.8 No Laundering. The Parties understand and acknowledge
that the licenses, releases, and covenants granted to Affymetrix and its Affiliates by Enzo hereunder are intended to cover only
the bona fide products or services of Affymetrix and its Affiliates and are not intended to cover patent laundering activities
(i.e., activities that are undertaken solely for the purpose of improperly extending licensed rights to cover any activity of any
third party acting outside the scope of Affymetrix’s or its Affiliates’ licensed activities). The Parties further agree that a

    	 

    	

    

purchase of a product from a supplier and resale of such product
in substantially the same form back to the same suppler is not licensed under this Agreement. Nothing in this Agreement shall be
construed to license sham sales or sham service contracts executed by Affymetrix or any of its Affiliates with any third party
solely for the purpose of improperly extending licensed rights to cover any activity of any third party acting outside the scope
of Affymetrix’s (or its Affiliates’) licensed activities.

 

6.9 Severability. If any provision of this Agreement
is held to be illegal or unenforceable, such provision shall be limited or eliminated to the minimum extent necessary so that the
remainder of this Agreement will continue in full force and effect and be enforceable. The Parties agree to negotiate in good faith
an enforceable substitute provision for any invalid or unenforceable provision that most nearly achieves the intent of such provision.

 

6.10 Entire Agreement. The Parties hereby agree that
(i) this is an enforceable agreement; (ii) this Agreement constitutes the entire and only understanding of each of them with respect
to the subject matter of the Agreement, and merges, supersedes and cancels all previous agreements and understandings, whether
oral or written, with respect to the subject matter of the Agreement; (iii) no oral explanation or oral information by any Party
hereto shall alter the meaning or interpretation of this Agreement; (iv) the terms and conditions of this Agreement may be altered,
modified, changed or amended only by a written agreement that identifies itself as an amendment to this Agreement and is executed
by duly authorized representatives of Enzo and Affymetrix; (v) the language of this Agreement has been approved by counsel for
each of them, and shall be construed as a whole according to its fair meaning; and (vi) none of the them (nor their respective
counsel) shall be deemed to be the draftsman of this Agreement in any action which may hereafter arise with respect to the Agreement.

 

6.11 Modification; Waiver. No modification or amendment
to this Agreement, nor any waiver of any rights, will be effective unless assented to in writing by the Party to be charged, and
the waiver of any breach or default will not constitute a waiver of any other right hereunder or any subsequent breach or default.

 

6.12 Construction; Language. Any rule of construction
to the effect that ambiguities are to be resolved against the drafting Party will not be applied in the construction or interpretation
of this Agreement. As used in this Agreement, the words “include” and “including” and variations thereof,
will not be deemed to be terms of limitation, but rather will be deemed to be followed by the words “without limitation.”
The headings in this Agreement will not be referred to in connection with the construction or interpretation of this Agreement.
This Agreement is in the English language only, which language shall be controlling in all respects, and all notices under this
Agreement shall be in the English language.

 

6.13 Counterparts. This Agreement may be executed in
counterparts or duplicate originals, both of which shall be regarded as one and the same instrument, and which shall be the official
and governing version in the interpretation of this Agreement. This Agreement may be executed by facsimile signatures or other
electronic means and such signatures shall be deemed to bind each Party as if they were original signatures.

    	 

    	

    

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement
to be signed below by their respective duly authorized officers.

 

Enzo Life Sciences, Inc.

 

	By:	/s/ Barry W. Weiner	 
	 	 	 
	Name: 	 	 
	 	 	 
	Title:	President	 
	 	 	 
	Date:	10/9/15	 

 

Affymetrix,
Inc.

 

	By:	/s/ Frank Whitney	 
	 	 	 
	Name: 	 	 
	 	 	 
	Title:	Chief Executive Officer	 
	 	 	 
	Date:	10/8/15	 
	 	 	 
	By:	/s/ Gavin Wood	 
	 	 	 
	Name:	 	 
	 	 	 
	Title:	Chief Financial Officer	 
	 	 	 
	Date:	10/9/15	 

    	 

    	

    

EXHIBIT A

 

STIPULATED MOTION FOR DISMISSAL OF
LITIGATION

 

UNITED STATES DISTRICT COURT

OF DELAWARE

 

	ENZO LIFE SCIENCES, INC.	)	CASE NO. CV 12-CV-433-LPS
	 	)	 
	vs.	) 	JOINT STIPULATION OF DISMISSAL
	 	)	WITH PREJUDICE
	AFFYMETRIX, INC.	)	 
	 	) 	The Hon. Leonard Stark
	Defendant.	)	Chief United States District Court Judge
	 	)	 
	 	)	 

 

Pursuant to Rule 41(a)(1)(A)(ii) of the Federal
Rules of Civil Procedure, Plaintiff, Enzo Life Sciences, Inc., and Defendant Affymetrix, Inc., by and through their respective
counsel, hereby stipulate to the dismissal with prejudice of all claims in this action. Each party shall bear its own attorneys’
fees and costs.

 

	 	 	Respectfully submitted,	 
	 	 	 	 
	FARNAN LLP	 	MORRIS NICHOLS ARSHT &TUNNELL
    LLP
	 	 	 
	 	 	 	 
	Brian E. Farnan (#4089)	 	Jack B. Blumenfeld (#1014)	 
	919 North Market Street, 12th Flr	 	Derek J. Fahnestock (#4705)	 
	Wilmington, DE 19801	 	1201 North Market Street	 
	(302) 777-0336	 	P.O. Box 1347	 
	bfarnan@farnanlaw.com	 	Wilmington, DE 19899	 
	 	 	(302) 658-9200	 
	Attorneys for Plaintiff	 	jblumenfeld@mnat.com	 
	Enzo Life Sciences, Inc.	 	dfahnestock@mnat.com	 
	 	 	 	 
	 	 	Attorneys for Defendant	 
	 	 	Affymetrix Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00250-of-00352.parquet"}]]